BioWorld

Aug. 11, 2004

View Archived Issues

Amgen Starting Phase III Trials With Treatment For Bone Loss

As promised, Amgen Inc. began dosing patients in two pivotal Phase III trials of AMG 162, its fully human monoclonal antibody designed to treat post-menopausal osteoporosis (PMO) and treatment-induced bone loss. (BioWorld Today) Read More

Pharmasset Raises $40M In Series D For HIV Candidates

Read More

Bioenvision Begins Pivotal Trial Of Clofarabine For AML In Europe

Read More

QLT Enlists Array To Assist With Work On Cancer Targets

Read More

Brain Research Firm Neurome Buys Digital Gene Technologies

Read More

Other News To Note

Read More

Appointments And Advancements

Read More